A Phase 1 Dose Escalation Study of Hepatic Intra-Arterial Administration of TKM 080301 (Lipid Nanoparticles Containing siRNA Against the PLK1 Gene Product) in Patients With Colorectal, Pancreas, Gastric, Breast, Ovarian and Esophageal Cancers With Hepatic Metastases.

Trial Profile

A Phase 1 Dose Escalation Study of Hepatic Intra-Arterial Administration of TKM 080301 (Lipid Nanoparticles Containing siRNA Against the PLK1 Gene Product) in Patients With Colorectal, Pancreas, Gastric, Breast, Ovarian and Esophageal Cancers With Hepatic Metastases.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 19 May 2017

At a glance

  • Drugs TKM PLK1 (Primary)
  • Indications Breast cancer; Colorectal cancer; Liver cancer; Liver metastases; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 25 Jun 2012 Actual end date (Jun 2012) added as reported by ClinicalTrials.gov.
    • 25 Jun 2012 Additional lead trial investigator (Thomas S Uldrick) identified and actual patients number (1) added as reported by ClinicalTrials.gov.
    • 27 Mar 2012 Status changed from recruiting to discontinued according to a Tekmira media release. Proof-of-concept of LNP technology was established based on interim results from Alnylam's programmes that utilise Tekmira's LNP technology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top